Neurology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.
The authors evaluated the long-term efficacy and safety of botulinum toxin type A (BTX-A) in poststroke spasticity patients who completed a 12-week placebo-controlled study and received multiple open-label treatments with 200 to 240 U BTX-A for 42 weeks. Significant and sustained improvements were observed for Disability Assessment and Ashworth scores. Adverse events were generally mild. This extension of a double-blind study demonstrates that repeated treatments of BTX-A significantly improve function and tone in spasticity.
-
Randomized Controlled Trial Clinical Trial
Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
To determine the effect of donepezil in treating memory and cognitive dysfunction in multiple sclerosis (MS). ⋯ Donepezil improved memory in MS patients with initial cognitive impairment in a single center clinical trial. A larger multicenter investigation of donepezil in MS is warranted in order to more definitively assess the efficacy of this intervention.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects.
Using identical methods, three simultaneous placebo-controlled trials of topiramate for painful diabetic neuropathy (PDN) did not reach significance. This independent yet concurrent placebo-controlled trial used different methods to assess topiramate efficacy and tolerability in PDN. ⋯ Topiramate monotherapy reduced pain and body weight more effectively than placebo in patients with painful diabetic neuropathy.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
To evaluate the efficacy and safety of the acetylcholinesterase inhibitor donepezil in a placebo-controlled trial in patients with mild cognitive impairment (MCI). ⋯ Although significant treatment effects were not seen in the primary efficacy measures, outcomes on secondary measures suggest promising directions for further evaluation of donepezil treatment in patients with MCI.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Menstrually associated migraine (MAM) is often prolonged and difficult to manage with conventional therapies. Frovatriptan is a new selective 5HT(1B/1D) receptor agonist indicated for short-term management of migraine. It has a long half-life and good tolerability. These characteristics suggest that frovatriptan may be useful for the intermittent prevention of MAM. ⋯ Frovatriptan given prophylactically for 6 days was effective in reducing the incidence of menstrually associated migraine. More than half of patients who used frovatriptan 2.5 mg BID had no menstrually associated migraine headache during the 6-day perimenstrual period. The findings are consistent with the long duration of action and good tolerability of frovatriptan observed in short-term migraine management.